AAAyşe Tuğşen AYDEMİR

Ayşe Tuğşen AYDEMİR

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ayşe Tuğşen AYDEMİR has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrative genomic and functional characterization of ADAMTS3 reveals its inflammatory regulation via NF‐κB and STAT3 pathways in osteosarcoma

    by Ehed Muhammed Aymaz, Meltem Alper, Feyza Nur Sav, Tuğşen Aydemir, Feray Köçkar

    Osteosarcoma (OS) is an aggressive bone malignancy characterized by genomic instability and extensive extracellular matrix (ECM) remodeling. Members of the ADAMTS family are matrix‐associated proteases implicated in tumorigenesis; however, their roles in OS remain poorly defined. This study provides a comprehensive genomic, transcriptomic, and functional analysis of the ADAMTSs in OS, with particular focus on ADAMTS‐3. Copy number alterations and mRNA expressions of ADAMTS genes were analyzed using the TCGA datasets. Gene set enrichment analysis and co‐expression analyses identified biological processes associated with ADAMTS‐3. Mechanistic studies investigated tumor necrosis factor‐alpha (TNF‐α) regulation of ADAMTS‐3 in OS cells. Genomic profiling revealed frequent amplification and high mRNA expression of ADAMTS4, ADAMTS12, ADAMTS16, and ADAMTS17, indicating potential oncogenic activity. ADAMTS‐3 was markedly overexpressed in OS tissues and cell lines, showing strong positive correlations with inflammatory (IL6, STAT3, NF‐κB) and matrix‐remodeling (MMP2, MMP9) genes. Functional enrichment indicated that ADAMTS‐3 is associated with ECM organization, immune response regulation, and epithelial‐mesenchymal transition. Mechanistically, TNF‐α induced ADAMTS‐3 transcription via activation of MEK, PI3K, JNK, and NF‐κB pathways, with STAT3 and NF‐κB by enhancing promoter activity. These findings identify ADAMTS‐3 as an inflammation‐responsive gene that links inflammatory signaling to ECM remodeling and tumor invasiveness in OS, representing a potential molecular bridge.

  • C/EBPα Mediated Transcriptional Regulation of Human ADAMTS-3 Gene and Collagen Expression in Osteosarcoma Cells

    by Meltem Alper, Tugsen Aydemir, Feray Köçkar

    ADAMTS-3 is a procollagen amino proteinase mainly expressed in type II collagen-rich tissues and its primary function is to maturate amino ends of the type II collagen precursors. This maturation process allows correct fibril formation. ADAMTS-3 also has a tumor-suppressive function by regulating the fibronectin expression in the ECM. C/EBPα is a transcription factor playing a pivotal role in the cell cycle regulation. Dysregulations in the C/EBPα expression have been reported in solid tumors. C/EBPα expression has been identified to be associated with the metabolism and prognosis of a malignant bone tumor, osteosarcoma (OS). High heterogeneity, metastasis capability, and recurrence lead to poor prognosis and survival rates in OS. Multiple genetic and epigenetic factors affect OS development. Alterations in the ECM elements are closely related to OS development and progression. According to the in-silico analyses, the ADAMTS-3 promoter includes multiple C/EBPα binding sites suggesting that C/EBPα could have a regulatory effect on ADAMTS-3 transcriptional regulation. In the present study, over-expression of the C/EBPα decreased ADAMTS-3 mRNA and protein levels in Saos-2 and MG-63 osteosarcoma models. Ectopic expression of the C/EBPα also led to alterations in some fibrillar collagen expression levels. Enhanced C/EBPα levels resulted in an increase in the type I and II collagen expression levels but didn’t change the type III collagen expression level in Saos-2 cells.

  • Expression Pattern of ADAMTS-3 (A Disintegrin and Matrix Metalloproteinase Type,1 Motif 3) in Normal and Cancer Cell Lines

    by Meltem Alper, A.TUğşen Aydemi̇r, Feray Köçkar

    ADAMTS-3 is a procollagen N- proteinase whose main function is to cleave procollagen II, the principal collagen of the cartilage and bone. This maturation process provides accurate fibril conformation for tissues. Along with collagen II, ADAMTS-3 can also process some other extracellular matrix components such as collagen III and fibronectin. ADAMTS mediated processing of the extracellular matrix components has considerable importance in both normal and pathological circumstances. Therefore, substrate specificities and the tissue expression profiles of the family members have become a hot topic. Further, altered expressions of the family members have been elucidated in some tumor types. Therefore, protumor and /or tumor suppressor functions of them is being investigated. The expression profile of the ADAMTS-3 has been studied only in a few normal and cancer tissues. Knowledge of the expression patterns of the ADAMTS-3 in cell lines are rather limited. In the present study, we determined ADAMTS-3 mRNA (sqRT-PCR) and protein expression levels (western-blot) in normal HUVEC, and cancer cell lines, namely, Saos-2, MG-63, DU-145, PC-3, Hep3B and PANC-1 cells. ADAMTS-3 was highly expressed in HUVEC, Saos-2, MG-63, and PC-3 cells. These findings will be fundamental for future studies that will be performed on ADAMTS-3 transcriptional regulation studies specific cancer types and also defining of the ADAMTS-3 contribution on the development and metastasis of specific cancer types.

  • Multidrug resistance gene expression response to cisplatin and 5FU treatment in hepatoma, prostate and colon cancer cells

    by Hatice Yildirim, Ayşe Tuğşen AYDEMİR

    Variable expression of drug transporters at the plasma membrane of tumor cells contributed to drug resistance. The aim of the present study was to explore the expression levels of MRP2 and MRP3genes in Cisplatin and 5 fluorouracil (5FU) treated Hep3B, PC3 and HT29 cell lines. MTT assay was used to determine the cytotoxic effects of cisplatin and 5FU. The results from the MTT assay revealed that PC3 cell line is the most sensitive for cisplatin treatment presenting the lowest IC50 value (0.5 µg/ml) for 48h. 5FU treatment altered the proliferation of PC3 cells with the IC50 values 6.0 µg/ml for 48 h and 8.2 µg/ml for 72h. The mRNA expression levels of MRP2 and MRP3 were determined by quantitative reverse transcription polymerase chain reaction. qRT-PCR results revealed that while the expression levels of MRP3 mRNA was generally down regulated in all cell lines treated with cisplatin and 5FU, MRP2 was upregulated in PC3 and Hep3B cells.